SCHEMBL8511124

SCHEMBL8511124

NC(CO)c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.45
HTR3E A5X5Y0 1/20 0.45
HTR3B O95264 1/20 0.45
HTR3A P46098 1/20 0.45
HTR3D Q70Z44 1/20 0.45
HTR3C Q8WXA8 1/20 0.45
AURKA O14965 1/20 0.44
RPS6KB1 P23443 1/20 0.44
ADRB2 P07550 5/20 0.43
ADRB1 P08588 1/20 0.43
KDR P35968 1/20 0.41
PDK1 Q15118 1/20 0.41
NPFFR2 Q9Y5X5 3/20 0.40
NPFFR1 Q9GZQ6 2/20 0.40
NOTUM Q6P988 1/20 0.40
AKR1C3 P42330 2/20 0.39
AKR1C2 P52895 2/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
S1PR1 P21453 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8511122 1.00 IDO1 (0.45) IDO1HTR3EHTR3BHTR3AHTR3D
SCHEMBL8510693 0.87 ADRB2 (0.43) ADRB2ADRB1NOTUM
SCHEMBL8510697 0.87 ADRB2 (0.43) ADRB2ADRB1NOTUM
SCHEMBL15157366 0.83 IDO1 (0.45) IDO1HTR3EHTR3BHTR3AHTR3D
SCHEMBL14981099 0.83 IDO1 (0.45) IDO1HTR3EHTR3BHTR3AHTR3D
SCHEMBL15758538 0.83 IDO1 (0.42) IDO1HTR3EHTR3BHTR3AHTR3D
SCHEMBL16464215 0.81 TRPV3 (0.40) ADRB2ADRB1
SCHEMBL8511924 0.81 TRPV3 (0.40) ADRB2ADRB1
SCHEMBL29256554 0.81 PYGL (0.46) IDO1HTR3EHTR3BHTR3AHTR3D
SCHEMBL29256556 0.81 PYGL (0.46) IDO1HTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2643313-B9 QUINAZOLINE CARBOXAMIDE AZETIDINES MERCK PATENT GMBH (DE) 2017-02-22 EP disclosed
EP-2643313-B1 QUINAZOLINE CARBOXAMIDE AZETIDINES MERCK PATENT GMBH (DE) 2016-06-29 EP disclosed
US-8946247-B2 Quinazoline carboxamide azetidines MERCK PATENT GMBH (DE) 2015-02-03 US disclosed
EP-2643313-A1 QUINAZOLINE CARBOXAMIDE AZETIDINES Merck Patent GmbH (DE) 2013-10-02 EP disclosed
US-20130252942-A1 QUINAZOLINE CARBOXAMIDE AZETIDINES MERCK PATENT GMBH (DE) 2013-09-26 US disclosed
CN-103228649-A Quinazoline carboxamide azetidines MERCK PATENT GMBH 2013-07-31 CN disclosed
WO-2012069146-A1 QUINAZOLINE CARBOXAMIDE AZETIDINES MERCK PATENT GMBH (DE) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252942-A1 QUINAZOLINE CARBOXAMIDE AZETIDINES AZI2, NQO2, ABL1 IDO1 231/4885HTR3E 1694/4885HTR3B 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.